Humana (NYSE:HUM) Updates FY 2024 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 16.000- for the period, compared to the consensus EPS estimate of 16.150. The company issued revenue guidance of -.

Humana Trading Down 1.7 %

Shares of HUM opened at $235.78 on Friday. The firm’s 50-day moving average is $274.01 and its two-hundred day moving average is $321.71. Humana has a twelve month low of $213.31 and a twelve month high of $475.00. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $28.39 billion, a P/E ratio of 20.88, a PEG ratio of 2.15 and a beta of 0.53.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. On average, research analysts predict that Humana will post 16.14 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.50%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Analyst Ratings Changes

HUM has been the topic of several recent analyst reports. Royal Bank of Canada reduced their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. UBS Group dropped their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. Finally, Oppenheimer cut their target price on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.